Publication:
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

Issued Date

2015-11-01

Resource Type

Article

ISSN

19318405
08892229

DOI

10.1089/aid.2015.0034

Other identifier(s)

2-s2.0-84946706967

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

AIDS Research and Human Retroviruses. Vol.31, No.11 (2015), 1178-1186

Suggested Citation

Nicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, Sirinan Madnote, Dutsadee Inthawong, Somsak Chantakulkij, Surawach Rittiroongrad, Sorachai Nitayaphan, Punnee Pitisuttithum, Prasert Thongcharoen, Vinai Siriyanon, Charla A. Andrews, Susan W. Barnett, James Tartaglia, Faruk Sinangil, Donald P. Francis, Merlin L. Robb, Nelson L. Michael, Viseth Ngauy, Mark S. De Souza, Robert M. Paris, Jean Louis Excler, Jerome H. Kim, Robert J. O'Connell IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Research and Human Retroviruses. Vol.31, No.11 (2015), 1178-1186. doi:10.1089/aid.2015.0034 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36055

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

Author(s)

Nicos Karasavvas
 Chitraporn Karnasuta
 Hathairat Savadsuk
 Sirinan Madnote
 Dutsadee Inthawong
 Somsak Chantakulkij
 Surawach Rittiroongrad
 Sorachai Nitayaphan
 Punnee Pitisuttithum
 Prasert Thongcharoen
 Vinai Siriyanon
 Charla A. Andrews
 Susan W. Barnett
 James Tartaglia
 Faruk Sinangil
 Donald P. Francis
 Merlin L. Robb
 Nelson L. Michael
 Viseth Ngauy
 Mark S. De Souza
 Robert M. Paris
 Jean Louis Excler
 Jerome H. Kim
 Robert J. O'Connell

Other Contributor(s)

Armed Forces Research Institute of Medical Sciences, Thailand
 Mahidol University
 Chiang Mai University
 TECHNICAL RESOURCES INTERNATIONAL, INC.
 NOVARTIS VACCINES AND DIAGNOSTICS, INC.
 Sanofi Pasteur
 Global Solutions for Infectious Diseases
 Walter Reed Army Institute of Research
 HJF
 International Vaccine Institute, Seoul

Abstract

© Copyright 2015, Mary Ann Liebert, Inc. 2015. RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01-AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01-AE scaffolds was higher with the AIDSVAX®B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials.

Keyword(s)

Immunology and Microbiology
 Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/36055

Collections

Scopus 2011-2015